key: cord-0751252-35qxrola
authors: Bril, Fernando; Al Diffalha, Sameer; Dean, Mark; Fettig, David M.
title: Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?
date: 2021-04-20
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.04.003
sha: 92404094c710de3951a182f1687449d1341fdb14
doc_id: 751252
cord_uid: 35qxrola

nan

J o u r n a l P r e -p r o o f Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with the development of autoimmune processes [1] [2] [3] [4] . Molecular mimicry has been suggested as a potential mechanism for these associations 1 . In an in vitro study, Vojdani et al 5 showed that antibodies against this spike protein S1 of SARS-CoV-2 had high affinity against the following human tissue proteins: transglutaminase 3, transglutaminase 2, anti-extractable nuclear antigen, nuclear antigen, and myelin basic protein. As this is the same viral protein that the vaccine mRNA codes for, it is plausible that these vaccines may unmask autoimmune diseases in predisposed patients. Recently, several cases of immune thrombocytopenia (ITP) developing days after COVID-19 vaccination, have been reported to the Vaccine Adverse Event Reporting System (VAERS), reinforcing the possibility of vaccine-induced autoimmunity 6 .

We have recently treated a 35-year-old Caucasian female on her 3 rd month postpartum, who developed autoimmune hepatitis after COVID-19 vaccination. During pregnancy, she was diagnosed with gestational hypertension and started on labetalol 100mg bid. C-section was performed without any complications, and patient was discharged from the hospital on labetalol for blood pressure control. She resumed her job as a healthcare provider in mid-December, and received her first dose of Pfizer-BioNTech COVID-19 vaccine on January 4 th . After one week, she started developing generalized pruritus, then choluria, and finally noticed jaundice, presenting to the emergency room on day +13 after COVID-19 vaccination.

She had a normal physical exam, except for scleral icterus, jaundice and palpable hepatomegaly. In the emergency room, laboratories were significant for: bilirubin 4.8mg/dl, AST To our knowledge, this is the first reported episode of autoimmune hepatitis developing post-COVID-19 vaccination, raising concern regarding the possibility of vaccine-induced autoimmunity. As causality cannot be proven, it is possible that this association is just coincidental. However, severe cases of SARS-CoV-2 infection are characterized by an autoinflammatory dysregulation that contributes to tissue damage 1 . As the viral spike protein appears to be responsible for this 1, 5 , it is plausible that spike-directed antibodies induced by vaccination may also trigger autoimmune conditions in predisposed individuals. In support of this, several cases of ITP have been reported days after COVID-19 vaccination 6 .

Several atypical features of her presentation deserve further discussion. First, immunoglobulin G levels were not elevated as typically reported for autoimmune hepatitis. However, Hartl et al recently reported that ~10% of patients with autoimmune hepatitis had normal immunoglobulin G levels at presentation 7 . Second, histology showed presence of eosinophils, which are more commonly seen with drug or toxin induced liver injury. However, they can be found with frequency in cases of autoimmune hepatitis 8 . It is also possible that we could be in the presence of a vaccine-related drug-induced liver injury with features of autoimmune hepatitis, as previously described for nitrofurantoin or minocycline 9 . In line with this, patient has already started a prednisone taper, as patients with well documented drug-induced AIH do not typically show relapses after steroid discontinuation 10 . Finally, symptoms developed 6 days after vaccination, which instinctively appears as a short period of time. However, latency periods have previously been observed as short as days after vaccination in prior reports 6, 11 .

In summary, autoimmune hepatitis developed in a healthy 35-year-old female in her third month postpartum. Whether there exists a causal relationship between COVID-19 vaccination and the development of autoimmune hepatitis remains to be determined. We are hopeful that this manuscript will not discourage healthcare providers from getting and prescribing COVID-19

vaccines, but that it will raise awareness about potential side effects that will likely emerge as we continue to vaccinate more people. Only long-term follow-up of large cohorts of patients receiving the vaccine will answer the question as to whether it increases the risk of autoimmune conditions. Until then, healthcare providers are encouraged to remain vigilant. 

Covid-19 and autoimmunity

Immune Thrombocytopenic Purpura in a Patient with Covid-19

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

Guillain-Barre Syndrome Associated with SARS-CoV-2

Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Features and outcome of AIH patients without elevation of IgG

Role of Histopathology in Autoimmune Hepatitis

Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury

Drug-Induced Autoimmune Hepatitis: Response to Corticosteroids and Lack of Relapse After Cessation of Steroids

Transverse myelitis and vaccines: a multi-analysis